Effect of Suboccipital Release in Patients With Fibromyalgia Syndrome

Cairo University40 enrolled

Overview

This study was designed to examine the efficacy of suboccipital release in Patients With FMS and to provide preliminary evidence regarding its effects on pain and QOL by objectively measuring Cortisol level in FMS patien

Forty female patients with FM ( age : 20- 45 Years ) participated in the study after suing the consent form . Participants were randomly allocated assigned into 2 equal groups ( control group \[ G1 \] and study \[G2 \] ) . Group 1 received selected physical therapy programme. Group 2 recieved suboccipital release. All participants were assessed for cortisol and pain level by using visual analogues scale and neck disability scale. Also participants were assessed by pressure algometer for pain intensity. Participants were assessed for QOL by FIBROMYALGIA IMPACT QUESTIONNAIRE (FIQR) . treatment was done 3 sessions per weeks for successive 6 weeks pre and post assessment for all valuable were Done

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

SINGLE

Enrollment

Conditions

Fibromyalgia

Interventions

Suboccipital releaseOTHER

The ptients in this group recieve suboccipital release. The patient is positioned in a supine (lying on their back) position, allowing full relaxation of the cervical spine. The therapist places their fingertips or hands under the patient's occiput, making contact with the suboccipital muscles. Using gentle, sustained pressure, the therapist allows the weight of the head to create a release, often holding for 1-5 minutes. Subtle adjustments may be made, such as slight traction or rocking, to facilitate myofascial release and relaxation.

Eligibility

Sex: FEMALEMin age: 20 YearsMax age: 45 Years

Medical Language ↔ Plain English

Inclusion Criteria: * women between 20-45 years old, (ii) diagnoses according to the 2016 American College of Rheumatology criteria for fibromyalgia \[1\] * Symptoms have been present at a similar level for at least three months (iii) Absence of other disorders that causes similar symptoms: systemic lupus erethromatosis (SLE), rheumatoid arthritis (RA) and Lyme disease based on laboratory investigations (erythrocyte sedimentation rate (ESR), Anti anti-cyclic citrullinated peptide (Anti CCP), antinuclear antibody (ANA) and Rheumatoid factor(RF)). * Exclusion Criteria: * any medical, neurological, or psychiatric illness, use of strong opioids or other painkillers except paracetamol and/or ibuprofen, benzodiazepine, illicit drug or alcohol use, recent use of cannabis, pregnancy, breast feeding, and the presence of pain syndromes other than FM. Presence of other autoimmune disorders e.g.: rheumatoid arthritis and systemic lupus erethromatosus

Locations (1)

Faculty of physical therapy laps at cairo university

Cairo, Egypt

RECRUITING

Outcomes

Primary Outcomes

Cortisol level

Changes in pain from baseline to six weeks after begining of intervention

Time frame: Six weeks after begining of intervention

Secondary Outcomes

Fibromyalgia impact questionair

Changes of quality of life from baseline to six weeks after begining of interventio

Time frame: Six weeks after begining of intervention

Central Contacts

Rowida Abdelgleel, Lecturer

CONTACT

01152322678 rowidaabdelglel@gmail.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.